Latest Expert Opinions

Signal
Opinion
Expert
TOP PICK
TOP PICK
August 13, 2004
Looking for higher topline growth.
Qualcomm (QCOM-Q)
August 13, 2004
Looking for higher topline growth.
Gretchen Lash
Chief Executive Officer, Engemann Asset Management
Price
$69.170
Owned
Yes
TOP PICK
TOP PICK
August 13, 2004
Looking for higher topline growth.
Home Depot (HD-N)
August 13, 2004
Looking for higher topline growth.
Gretchen Lash
Chief Executive Officer, Engemann Asset Management
Price
$33.140
Owned
Yes
TOP PICK
TOP PICK
August 13, 2004

(Top Sell) With rising interest rates and high oil prices and slowing earnings growth can create some problems.

(Top Sell) With rising interest rates and high oil prices and slowing earnings growth can create some problems.

Robert Stovall
Chief Investment Officer, Wood Asset Management
Price
$17.860
Owned
No
TOP PICK
TOP PICK
August 13, 2004
In a turnaround mode. Had been hurt by competition from China. Near its low.
In a turnaround mode. Had been hurt by competition from China. Near its low.
Robert Stovall
Chief Investment Officer, Wood Asset Management
Price
$20.880
Owned
Yes
TOP PICK
TOP PICK
August 13, 2004
In a turnaround mode. Trying to refocus the public image positively. A global powerhouse.
Microsoft (MSFT-Q)
August 13, 2004
In a turnaround mode. Trying to refocus the public image positively. A global powerhouse.
Robert Stovall
Chief Investment Officer, Wood Asset Management
Price
$27.020
Owned
Yes
TOP PICK
TOP PICK
August 13, 2004
Feels that oils are going to lead in earnings growth.
BP PLC (BP-N)
August 13, 2004
Feels that oils are going to lead in earnings growth.
Robert Stovall
Chief Investment Officer, Wood Asset Management
Price
$53.840
Owned
Yes
TOP PICK
TOP PICK
August 13, 2004
Growing very well. Their biggest drug is for high blood pressure but also have a good product line for cancer treatment. Not many patent exposures in the near-term.
Novartis AG (NVS-N)
August 13, 2004
Growing very well. Their biggest drug is for high blood pressure but also have a good product line for cancer treatment. Not many patent exposures in the near-term.
Samuel D. Isaly
Portfolio Manager, Eaton Vance Worldwide
Price
$45.760
Owned
Yes